Galectin Therapeutics Q2 FY26 net loss widens 21.17% to $9.11 million
Reuters2026/08/14 11:52- Galectin Therapeutics posted a GAAP net loss of USD 9.11 million, widening from USD 7.52 million a year earlier.
- Loss per share widened to USD 0.14 from USD 0.12, while operating loss narrowed to USD 3.98 million from USD 4.63 million.
- Research and development expense fell 34% to USD 2.14 million, while general and administrative costs rose 35% to USD 1.85 million.
- Cash and cash equivalents declined to USD 13.27 million from USD 17.72 million at Dec. 31, 2025.
- FDA Type C meeting set a regulatory path; Phase 3 protocol filing targeted for Q3 2026, with funding and partnership discussions ongoing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
